Alzheimer’s drug from Eisai, Biogen gets FDA accelerated approval
In trials, Alzheimer’s drug Leqembi clinically demonstrated that it can slow cognitive decline by 27% in people with Alzheimer’s disease, data which facilitated the FDA’s approval.
By Fiona Rutherford and Robert Langreth, bloomberg
Eisai Co. and its partner Biogen Inc. gained initial US regulatory clearance for lecanemab, the first treatment clearly shown to slow the advance of brain-wasting Alzheimer’s disease.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Investigation questions FDA approval of Aduhelm
For subscribers
